Exscientia: Dundee drug discovery firm raises £400 million to 'reshape industry'
Exscientia CEO Professor Andrew Hopkins Dundee life sciences firm Exscientia has access to almost £400 million after its latest fundraising round. The Dundee University spin-out company uses artificial intelligence (AI) to design drugs. Its latest funding round raised $225m (£162m) with an additional $300m (£216m) available from SoftBank at Exscientia’s discretion. What will the money be used for? Chief executive Andrew Hopkins said the investment would be used to expand the firm’s drug pipeline and discovery capabilities. He said: “All of our investors share Exscientia’s vision to...
Source: thecourier.co.uk